🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

3 Capsule(s) Serving Size
30 Servings
Other Combinations Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

50 mcg (63% DV)
✅ Within RDA (0.4× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.05mg
10 mg (500% DV)
📊 7.7× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 10mg UL 100mg
400 mcg (100% DV)
✅ Within RDA (1.0× RDA of 0.4 mg) 📚 225 studies (Tier A: 10, B: 105)
RDA 0.4mg This product: 0.4mg UL 1.0mg
30 mcg (500% DV)
📊 12.5× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.03mg
Calcium
228 mg (23% DV)
Phosphorous
229 mg (23% DV)
47 mg (12% DV)
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 47mg
Sodium
48 mg (2% DV)
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 1000mg
EDTA
300 mg
Malic Acid
300 mg
📊 Market median: 600.0mg (7 products) 📚 39 studies (Tier A: 2, B: 13)
This product: 100mg
Grapeseed extract
200 mg
📊 Market median: 200.0mg (198 products) 📚 6 studies — no high-quality reviews
This product: 50mg
50 mg
📊 Market median: 496.0mg (192 products) 📚 20 studies — no high-quality reviews
This product: 50mg
📊 Market median: 500.0mg (497 products) 📚 132 studies (Tier A: 0, B: 40)
This product: 50mg

Other Ingredients

Gelatin Magnesium Stearate Microcrystalline Cellulose

Label Claims — Verification

All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Children 4 or More Years of Age Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: Take three capsules daily or as directed by your healthcare professional.

⚠️ Warnings & Precautions

Caution: Consult with your healthcare professional prior to using this product if you are pregnant, nursing, taking medications(s), have a medical condition, or are under the age of 12 years.

KEEP OUT OF REACH OF CHILDREN.

Additional Information

SCIENTIFICALLY FORMULATED DOCTOR APPROVED

STORE IN A COOL, DRY PLACE.

Oral Chelation for Cardiovascular & Bone Health*

This product is manufactured in a NSF GMP registered facility.

Contains the World's Finest Ingredients.

MADE IN U.S.A.

300-TARSC-A

Product Details

DSLD Entry Date 2012-12-21
Product Type Other Combinations
Form Capsule
Brand True Health
DSLD ID 16678
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →